en
Scientific article
Open access
English

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Published inAnnals of the rheumatic diseases, vol. 72, no. 4, p. 482-492
Publication date2013
Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

Keywords
  • Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
  • Antirheumatic Agents/administration & dosage/adverse effects
  • Arthritis, Rheumatoid/drug therapy/immunology
  • Drug Monitoring/methods
  • Humans
  • Inflammation/drug therapy/immunology
  • Interleukin-6/antagonists & inhibitors
  • Receptors, Interleukin-6/antagonists & inhibitors
Citation (ISO format)
SMOLEN, Josef S et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. In: Annals of the rheumatic diseases, 2013, vol. 72, n° 4, p. 482–492. doi: 10.1136/annrheumdis-2012-202469
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0003-4967
524views
328downloads

Technical informations

Creation01/22/2015 4:20:00 PM
First validation01/22/2015 4:20:00 PM
Update time03/14/2023 10:45:06 PM
Status update03/14/2023 10:45:05 PM
Last indexation08/29/2023 2:28:32 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack